|Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk|
G Liu, S Gramling, D Munoz, D Cheng, AK Azad, M Mirshams, Z Chen, ...
Oncogene 30 (29), 3295-3304, 2011
|Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer SurvivalGenetic Sequence Variants and Head and Neck Cancer Survival|
AK Azad, I Bairati, E Samson, D Cheng, M Mirshams, X Qiu, S Savas, ...
Clinical Cancer Research 18 (1), 196-206, 2012
|Association of two BRM promoter polymorphisms with head and neck squamous cell carcinoma risk|
JR Wang, SJB Gramling, DP Goldstein, D Cheng, D Chen, AK Azad, ...
Carcinogenesis 34 (5), 1012-1017, 2013
|Socioeconomic status, human papillomavirus, and overall survival in head and neck squamous cell carcinomas in Toronto, Canada|
KP Chu, S Habbous, Q Kuang, K Boyd, M Mirshams, FF Liu, ...
Cancer epidemiology 40, 102-112, 2016
|Genetic sequence variants and the development of secondary primary cancers in patients with head and neck cancers|
AK Azad, I Bairati, E Samson, D Cheng, L Cheng, M Mirshams, S Savas, ...
Cancer 118 (6), 1554-1565, 2012
|Measuring financial toxicity incurred after treatment of head and neck cancer: Development and validation of the Financial Index of Toxicity questionnaire|
K Hueniken, CM Douglas, AR Jethwa, M Mirshams, L Eng, A Hope, ...
Cancer 126 (17), 4042-4050, 2020
|Two BRM promoter insertion polymorphisms increase the risk of early‐stage upper aerodigestive tract cancers|
KM Wong, X Qiu, D Cheng, AK Azad, S Habbous, P Palepu, M Mirshams, ...
Cancer Medicine 3 (2), 426-433, 2014
|Multiple imputation and clinico‐serological models to predict human papillomavirus status in oropharyngeal carcinoma: an alternative when tissue is unavailable|
J Ren, W Xu, J Su, X Ren, D Cheng, Z Chen, N Bender, M Mirshams, ...
International journal of cancer 146 (8), 2166-2174, 2020
|HPV status improves classification of head and neck gray zone cancers|
J Ren, W Xu, J Su, X Ren, N Bender, S Habbous, JR de Almeida, ...
Journal of Dental Research 98 (8), 879-887, 2019
|Two BRM promoter polymorphisms and risk of early stage (Stage I-II) upper aerodigestive tract cancer risk|
K Wong, X Qiu, D Cheng, AK Azad, P Palepu, M Mirshams, D Patel, ...
J Clin Oncol 30 (Suppl), 2012
|The effect of two BRM promoter variants on the risk of stage I/II upper aerodigestive tract cancers.|
KM Wong, X Qiu, D Cheng, AK Azad, PR Palepu, M Mirshams, D Patel, ...
Journal of Clinical Oncology 30 (15_suppl), 10522-10522, 2012
|Out‐of‐pocket costs associated with head and neck cancer treatment|
MN Khan, K Hueniken, M Manojlovic‐Kolarski, L Eng, M Mirshams, ...
Cancer Reports 5 (7), e1528, 2022
|Nicotine dependence as a risk factor for upper aerodigestive tract (UADT) cancers: A mediation analysis|
S Thomas, JC Carroll, MC Brown, Z Chen, M Mirshams, D Patel, K Boyd, ...
Plos one 15 (8), e0237723, 2020
|Association between genetic variants and cisplatin-induced nephrotoxicity: a genome-wide approach and validation study|
Z Zazuli, C de Jong, W Xu, SJH Vijverberg, R Masereeuw, D Patel, ...
Journal of Personalized Medicine 11 (11), 1233, 2021
|A genome-wide association study of non-HPV-related head and neck squamous cell carcinoma identifies prognostic genetic sequence variants in the MAP-kinase and hormone pathways|
AK Azad, I Bairati, X Qiu, H Girgis, L Cheng, D Waggott, D Cheng, ...
Cancer Epidemiology 42, 173-180, 2016
|The basket or umbrella real-world observational study (BUROS) design for molecular cancer subtypes|
G Liu, S Raptis, M Mirshams, D Patel, S Chotai, A Ghattas, A Zarrin, A Stitt, ...
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY 29, 421-421, 2020
|947P Association between genetic variants and cisplatin nephrotoxicity: A genome-wide approach|
Z Zazuli, W Xu, S Vijverberg, R Masereeuw, M Mirshams, K Khan, ...
Annals of Oncology 31, S674, 2020
|Cisplatin-induced ototoxicity in head and neck squamous cell carcinoma (HNSCC) patients treated with chemoradiation: The role of WFS1 and ABCC2 heritable variants.|
M Mahler, Y Zhang, K Hueniken, MC Brown, Z Chen, M Mirshams, ...
Journal of Clinical Oncology 36 (15_suppl), 6048-6048, 2018
|The Willingness Of Cancer Outpatients To Complete Patient-Reported Outcome Measures Outside Of The Clinic|
V Ho, Y Song, C Brown, A Vennettilli, L Eng, A Zarrin, A Dobriyal, L Chen, ...
Value in Health 18 (7), A470-A471, 2015
|Using tablet technology in routine patient-reported outcome measure surveys to improve cancer quality care: A patient acceptability assessment.|
V Pat, C Brown, A Vennettilli, A Zarrin, A Dobriyal, L Chen, M Mirshams, ...
Journal of Clinical Oncology 32 (30_suppl), 155-155, 2014